{"id":"https://openalex.org/W2104036010","doi":"https://doi.org/10.1158/1535-7163.mct-09-1148","title":"High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells","display_name":"High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells","alternate_titles":[],"publication_year":2010,"publication_date":"2010-06-01","ids":{"openalex":"https://openalex.org/W2104036010","doi":"https://doi.org/10.1158/1535-7163.mct-09-1148","mag":"2104036010","pmid":"https://pubmed.ncbi.nlm.nih.gov/20530715"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-09-1148","doi":"https://doi.org/10.1158/1535-7163.mct-09-1148","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-09-1148","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2104036010"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066722357","display_name":"Peter D. Caie","orcid":"https://orcid.org/0000-0002-0031-9850","observed_orcids":["https://orcid.org/0000-0002-0031-9850"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210092990","display_name":"Tessella (United Kingdom)","ror":"https://ror.org/00fpcwp04","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210092990"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Peter D. Caie","raw_affiliation_strings":["Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I188950975","https://openalex.org/I4210092990"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003994562","display_name":"Rebecca E. Walls","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210092990","display_name":"Tessella (United Kingdom)","ror":"https://ror.org/00fpcwp04","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210092990"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rebecca E. Walls","raw_affiliation_strings":["Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I188950975","https://openalex.org/I4210092990"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014349923","display_name":"Alexandra Ingleston-Orme","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210092990","display_name":"Tessella (United Kingdom)","ror":"https://ror.org/00fpcwp04","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210092990"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alexandra Ingleston-Orme","raw_affiliation_strings":["Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I188950975","https://openalex.org/I4210092990"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043830629","display_name":"Sandeep Daya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210092990","display_name":"Tessella (United Kingdom)","ror":"https://ror.org/00fpcwp04","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210092990"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sandeep Daya","raw_affiliation_strings":["Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I188950975","https://openalex.org/I4210092990"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022667948","display_name":"Thomas M. Houslay","orcid":"https://orcid.org/0000-0001-5592-9034","observed_orcids":["https://orcid.org/0000-0001-5592-9034"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210092990","display_name":"Tessella (United Kingdom)","ror":"https://ror.org/00fpcwp04","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210092990"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Tom Houslay","raw_affiliation_strings":["Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I188950975","https://openalex.org/I4210092990"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Rob Eagle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210092990","display_name":"Tessella (United Kingdom)","ror":"https://ror.org/00fpcwp04","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210092990"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rob Eagle","raw_affiliation_strings":["Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I188950975","https://openalex.org/I4210092990"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Mark E. Roberts","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210092990","display_name":"Tessella (United Kingdom)","ror":"https://ror.org/00fpcwp04","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210092990"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mark E. Roberts","raw_affiliation_strings":["Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom","School of Philosophy Psychology and Language Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I188950975","https://openalex.org/I4210092990"]},{"raw_affiliation_string":"School of Philosophy Psychology and Language Sciences","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066808283","display_name":"Neil O. Carragher","orcid":"https://orcid.org/0000-0001-5541-9747","observed_orcids":["https://orcid.org/0000-0001-5541-9747"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210092990","display_name":"Tessella (United Kingdom)","ror":"https://ror.org/00fpcwp04","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210092990"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Neil O. Carragher","raw_affiliation_strings":["Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Advanced Science and Technology Laboratory and 2Discovery Statistics, AstraZeneca R&D Charnwood, Loughborough, United Kingdom; 3GlaxoSmithKline, Molecular Discovery Research, Harlow, Essex, United Kingdom; and 4Tessella plc, 26 The Quadrant, Abingdon Science Park, Abingdon, Oxfordshire, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I188950975","https://openalex.org/I4210092990"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.2531,"has_fulltext":false,"cited_by_count":220,"citation_normalized_percentile":{"value":0.91786713,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"9","issue":"6","first_page":"1913","last_page":"1926"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12859","display_name":"Cell Image Analysis Techniques","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/1304","display_name":"Biophysics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12859","display_name":"Cell Image Analysis Techniques","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/1304","display_name":"Biophysics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10336","display_name":"Cancer Cells and Metastasis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/high-content-imaging","display_name":"high-content imaging","score":0.8790000081062317},{"id":"https://openalex.org/keywords/phenotypic-profiling","display_name":"phenotypic profiling","score":0.8659999966621399},{"id":"https://openalex.org/keywords/drug-response-signatures","display_name":"drug response signatures","score":0.9070000052452087},{"id":"https://openalex.org/keywords/tumor-cell-morphology","display_name":"tumor cell morphology","score":0.7649999856948853},{"id":"https://openalex.org/keywords/cell-based-assays","display_name":"cell-based assays","score":0.5070000290870667},{"id":"https://openalex.org/keywords/image-analysis-algorithms","display_name":"image analysis algorithms","score":0.9459999799728394},{"id":"https://openalex.org/keywords/multivariate-clustering","display_name":"multivariate clustering","score":0.8009999990463257},{"id":"https://openalex.org/keywords/kohonen-neural-network","display_name":"Kohonen neural network","score":0.7770000100135803},{"id":"https://openalex.org/keywords/k-nearest-neighbors-classification","display_name":"k-nearest neighbors classification","score":0.7919999957084656},{"id":"https://openalex.org/keywords/ovcar3","display_name":"OVCAR3","score":0.7739999890327454},{"id":"https://openalex.org/keywords/mcf-7-cells","display_name":"MCF-7 cells","score":0.9890000224113464},{"id":"https://openalex.org/keywords/polypharmacology","display_name":"polypharmacology","score":0.7390000224113464},{"id":"https://openalex.org/keywords/drug-mode-of-action","display_name":"drug mode of action","score":0.777999997138977}],"concepts":[{"id":"https://openalex.org/C157044486","wikidata":"https://www.wikidata.org/wiki/Q5754482","display_name":"High-content screening","level":3,"score":0.6994982361793518},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.6212481260299683},{"id":"https://openalex.org/C127716648","wikidata":"https://www.wikidata.org/wiki/Q104053","display_name":"Phenotype","level":3,"score":0.5129337310791016},{"id":"https://openalex.org/C2994119904","wikidata":"https://www.wikidata.org/wiki/Q1251001","display_name":"Drug response","level":3,"score":0.5000481605529785},{"id":"https://openalex.org/C6555983","wikidata":"https://www.wikidata.org/wiki/Q7181398","display_name":"Phenotypic screening","level":4,"score":0.49903082847595215},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4662443995475769},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.4629085958003998},{"id":"https://openalex.org/C187191949","wikidata":"https://www.wikidata.org/wiki/Q1138496","display_name":"Profiling (computer programming)","level":2,"score":0.44322407245635986},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.4320371747016907},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.33967018127441406},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.31600576639175415},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.3146641254425049},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2874954342842102},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.28158751130104065},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.1880587935447693},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.09308576583862305},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C111919701","wikidata":"https://www.wikidata.org/wiki/Q9135","display_name":"Operating system","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000465","descriptor_name":"Algorithms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007091","descriptor_name":"Image Processing, Computer-Assisted","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D010641","descriptor_name":"Phenotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016000","descriptor_name":"Cluster Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D025341","descriptor_name":"Principal Component Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057166","descriptor_name":"High-Throughput Screening Assays","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.mct-09-1148","doi":"https://doi.org/10.1158/1535-7163.mct-09-1148","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-09-1148","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:20530715","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20530715","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.876.7827","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.876.7827","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mct.aacrjournals.org/content/9/6/1913.full.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.7246000170707703,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W65738273","https://openalex.org/W121691410","https://openalex.org/W1540596182","https://openalex.org/W1560179018","https://openalex.org/W1967660686","https://openalex.org/W1985317603","https://openalex.org/W1991944021","https://openalex.org/W1993669821","https://openalex.org/W1998202992","https://openalex.org/W2008125086","https://openalex.org/W2017322644","https://openalex.org/W2041066856","https://openalex.org/W2056054628","https://openalex.org/W2056344676","https://openalex.org/W2061422463","https://openalex.org/W2075258506","https://openalex.org/W2083543572","https://openalex.org/W2092710950","https://openalex.org/W2095321243","https://openalex.org/W2097308038","https://openalex.org/W2099905447","https://openalex.org/W2107515803","https://openalex.org/W2108303909","https://openalex.org/W2120372267","https://openalex.org/W2145735068","https://openalex.org/W2149122422","https://openalex.org/W2150341677","https://openalex.org/W2151842905"],"related_works":["https://openalex.org/W4407911302","https://openalex.org/W2809739605","https://openalex.org/W2108303909","https://openalex.org/W2505317998","https://openalex.org/W1969545640","https://openalex.org/W2955333422","https://openalex.org/W3118251504","https://openalex.org/W4391931019","https://openalex.org/W3091346143","https://openalex.org/W7148707294"],"abstract_inverted_index":{"The":[0],"application":[1,91],"of":[2,18,24,27,36,39,70,92,120,144,152,186,190],"high-content":[3],"imaging":[4],"in":[5,15,79,108,199],"conjunction":[6],"with":[7,123],"multivariate":[8],"clustering":[9],"techniques":[10],"has":[11],"recently":[12],"shown":[13],"value":[14],"the":[16,68,90,118,150,180,184],"confirmation":[17],"cellular":[19,61],"activity":[20],"and":[21,52,76,96,135,141,169,173],"further":[22,116],"characterization":[23],"drug":[25,40],"mode":[26],"action":[28],"following":[29],"pharmacologic":[30,160,195],"perturbation.":[31],"However,":[32],"such":[33,145],"practical":[34],"examples":[35],"phenotypic":[37,53,74,106],"profiling":[38],"response":[41,54,107,161],"published":[42],"to":[43,49,59,103,138,182],"date":[44],"have":[45,179],"largely":[46],"been":[47],"restricted":[48],"cell":[50,80,85,113,165],"lines":[51],"markers":[55],"that":[56],"are":[57],"amenable":[58],"basic":[60],"imaging.":[62],"As":[63],"such,":[64],"these":[65,121,153],"approaches":[66,154],"preclude":[67],"analysis":[69,100,126],"both":[71],"complex":[72],"heterogeneous":[73],"responses":[75],"subtle":[77],"changes":[78],"morphology":[81],"across":[82,110,162],"physiologically":[83],"relevant":[84],"panels.":[86],"Here,":[87],"we":[88],"describe":[89,117],"a":[93,187],"cell-based":[94],"assay":[95],"custom":[97],"designed":[98,102],"image":[99],"algorithms":[101],"monitor":[104],"morphologic":[105],"detail":[109],"distinct":[111],"cancer":[112,164],"types.":[114],"We":[115,148],"integration":[119],"methods":[122,178],"automated":[124],"data":[125,146],"workflows":[127],"incorporating":[128],"principal":[129],"component":[130],"analysis,":[131],"Kohonen":[132],"neural":[133],"networking,":[134],"kNN":[136],"classification":[137],"enable":[139],"rapid":[140],"robust":[142],"interrogation":[143],"sets.":[147],"show":[149],"utility":[151],"by":[155],"providing":[156],"novel":[157,191],"insight":[158],"into":[159],"four":[163],"types,":[166],"Ovcar3,":[167],"MiaPaCa2,":[168],"MCF7":[170],"cells":[171],"wild-type":[172],"mutant":[174],"for":[175],"p53.":[176],"These":[177],"potential":[181],"drive":[183],"development":[185],"new":[188],"generation":[189],"therapeutic":[192],"classes":[193],"encompassing":[194],"compositions":[196],"or":[197],"polypharmacology":[198],"appropriate":[200],"disease":[201],"context.":[202]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2104036010","counts_by_year":[{"year":2026,"cited_by_count":31},{"year":2025,"cited_by_count":17},{"year":2024,"cited_by_count":15},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":14},{"year":2021,"cited_by_count":15},{"year":2020,"cited_by_count":23},{"year":2019,"cited_by_count":16},{"year":2018,"cited_by_count":14},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":14},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":12},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2016-06-24T00:00:00"}
